Autor(es): Almeida-Pinto, N ; Dschietzig, TB ; Brás-Silva C ; Adao, R
Data: 2023
Identificador Persistente: https://hdl.handle.net/10216/156795
Origem: Repositório Aberto da Universidade do Porto
Assunto(s): Ciências da Saúde, Ciências médicas e da saúde; Health sciences, Medical and Health sciences
The hormone relaxin-2 has emerged as a promising player in regulating the physiology of the cardiovascular system. Through binding to the relaxin family peptide receptor 1 (RXFP1), this hormone elicits multiple physiological responses including vasodilation induction, reduction of inflammation and oxidative stress, and angiogenesis stimulation. The role of relaxin-2, or its recombinant human form known as serelaxin, has been investigated in preclinical and clinical studies as a potential therapy for cardiovascular diseases, especially heart failure, whose current therapy is still unoptimized. However, evidence from past clinical trials has been inconsistent and further research is needed to fully understand the potential applications of relaxin-2. This review provides an overview of serelaxin use in clinical trials and discusses future directions in the development of relaxin-2 mimetics, which may offer new therapeutic options for patients with heart failure.
